Sphera Funds Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Sphera Funds Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-200,000	Closed	-$14.9M	–	89
2022 Q2	$14.9M	Buy	+200,000	New	+$15M	1.59%	14
2022 Q1	–	Sell	-220,000	Closed	-$24.6M	–	95
2021 Q4	$24.6M	Buy	+220,000	New	+$26.5M	2.71%	8

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Sphera Funds Management's XBI Position: Q4 2023 in Review

Sphera Funds Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2023, closing a stake of 50,000 shares — an estimated $3.71M sold.

Sphera Funds Management first reported a position in XBI in Q4 2018 and held it in 5 quarters. The position peaked at $32.5M in Q2 2022. 745 funds tracked by Wall St. Rank hold XBI as of Q4 2023.

Sphera Funds Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2023 after selling out during the quarter.
Sphera Funds Management sold 50,000 State Street SPDR S&P Biotech ETF shares in Q4 2023, an estimated $3.71M.
Sphera Funds Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2018 and held it in 5 quarters.
Sphera Funds Management's State Street SPDR S&P Biotech ETF position peaked at $32.5M in Q2 2022.
745 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2023.

Based on Sphera Funds Management's 13F filing for Q4 2023, filed 14 Feb 2024.